PRCT

Procept Biorobotics Corp

Add to Watchlist

Advanced Chart

38.410

-1.18(-2.981%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

40.980

Open

40.390

VWAP

38.94

Vol

2.35M

Mkt Cap

2.14B

Low

38.100

Amount

91.33M

EV/EBITDA(TTM)

Total Shares

51.42M

1.94B

EV/OCF(TTM)

P/S(TTM)

7.78

PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

93.56M

+35.28%

-0.277

-38.52%

96.43M

+41.33%

-0.263

-25%

80.76M

+38.36%

-0.420

+5%

Estimates Revision

The market is revising Upward the revenue expectations for PROCEPT BioRobotics Corporation (PRCT) for FY2025, with the revenue forecasts being adjusted by 0.13% over the past three months. During the same period, the stock price has changed by -27.69%.

Revenue Estimates for FY2025

Revise Upward

+0.13%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.24%

In Past 3 Month

Stock Price

Go Down

-27.69%

In Past 3 Month

12 Analyst Rating

100.47% Upside

Wall Street analysts forecast PRCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRCT is 77.00 USD with a low forecast of 68.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

3 Hold

0 Sell

Strong Buy

100.47% Upside

Current: 38.410

Low

68.00

Averages

77.00

High

85.00

100.47% Upside

Current: 38.410

Low

68.00

Averages

77.00

High

85.00

Piper Sandler

Matt O'Brien

Overweight

downgrade

$80 -> $55

2025-08-07

New

Reason

Piper Sandler

Matt O'Brien

Price Target

$80 -> $55

2025-08-07

New

downgrade

Overweight

Reason

Piper Sandler analyst Matt O'Brien lowered the firm's price target on Procept BioRobotics to $55 from $80 and keeps an Overweight rating on the shares. The firm notes the company reported Q2 results with sales that came in line with its preannouncement. Greenfield capital placements were a little light, but management reiterated its outlook for the full year and with a new CEO coming in this quarter, Piper doubts they want to set him up to miss. Overall, guidance was raised in line with the Q2.

Morgan Stanley

Overweight

downgrade

$71 -> $68

2025-07-15

Reason

Morgan Stanley

Price Target

$71 -> $68

2025-07-15

downgrade

Overweight

Reason

Morgan Stanley lowered the firm's price target on Procept BioRobotics to $68 from $71 and keeps an Overweight rating on the shares.The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.

Stephens

Mason Carrico

Overweight

initiated

$70

2025-07-09

Reason

Stephens

Mason Carrico

Price Target

$70

2025-07-09

initiated

Overweight

Reason

Stephens analyst Mason Carrico initiated coverage of Procept BioRobotics with an Overweight rating and $70 price target. The firm expects the company to post \"robust\" growth and margin expansion as adoption of Aquablation continues to expand. Aquablation is disrupting the benign prostatic hyperplasiamarket by taking share from existing procedures and capturing patients who historically delayed or avoided surgery, the analyst tells investors in a research note. Stephens believes expanding into prostate cancer has the potential to drive meaningful growth for Procept longer-term.

Oppenheimer

Perform

initiated

$323M

2025-07-07

Reason

Oppenheimer

Price Target

$323M

2025-07-07

initiated

Perform

Reason

Oppenheimer initiated coverage of Procept BioRobotics with a Perform rating. Procept has pioneered the Aquablation image-guided high-pressure, non-thermal waterjet ablation system for benign prostatic hyperplasia treatment. The firm notes that Aquablation's clinical value proposition has been robustly demonstrated in multiple clinical trials, with an impressive 4-year revenue CAGR of about 75%. FY25 guidance at $323M seems conservative, and a Q2 beat is expected, Oppenheimer adds. The firm's rating reflects its assessment of risk reward at these levels. Oppenheimer is constructive on the science but needs to get comfortable with utilization in a fragmented market and the risks with a potential 20% cut to physician payment rates.

BofA

Craig Bijou

Buy

downgrade

$104 -> $84

2025-04-25

Reason

BofA

Craig Bijou

Price Target

$104 -> $84

2025-04-25

downgrade

Buy

Reason

BofA analyst Craig Bijou lowered the firm's price target on Procept BioRobotics to $84 from $104 and keeps a Buy rating on the shares. Despite a "solid beat and raise," shares were down 6% as the company's inline system sales seem to have raised questions on future momentum, the analyst tells investors. However, the firm thinks the handpiece rebound and the improving utilization are better indicators, adds the analyst, who lowered the firm's target as peer multiples have fallen and also for an updated model following the Q1 results.

Morgan Stanley

Patrick Wood

Overweight

downgrade

$95 -> $71

2025-04-24

Reason

Morgan Stanley

Patrick Wood

Price Target

$95 -> $71

2025-04-24

downgrade

Overweight

Reason

Morgan Stanley analyst Patrick Wood lowered the firm's price target on Procept BioRobotics to $71 from $95 and keeps an Overweight rating on the shares. Despite a "solid first quarter print" and positive intra-quarter commentary, the stock has traded down significantly, which is "probably not deserved," the analyst tells investors. After speaking with management, the firm is "incrementally constructive" on elevated utilization trends continuing into the Q2 and thinks the pullback presents a buying opportunity, the analyst added.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Procept Biorobotics Corp (PRCT.O) is -34.16, compared to its 5-year average forward P/E of -27.49. For a more detailed relative valuation and DCF analysis to assess Procept Biorobotics Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-27.49

Current PE

-34.16

Overvalued PE

-12.93

Undervalued PE

-42.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-46.72

Current EV/EBITDA

-160.28

Overvalued EV/EBITDA

-7.18

Undervalued EV/EBITDA

-86.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

15.21

Current PS

6.75

Overvalued PS

22.78

Undervalued PS

7.64